Allergan , Inc. (NYSE:AGN) EVP Scott D. Sherman sold 14,500 shares of Allergan stock in a transaction dated Tuesday, April 22nd. The stock was sold at an average price of $155.82, for a total transaction of $2,259,390.00. Allergan, Inc. (NYSE:AGN) shares after opening at $163.18moved to $166.00on last trade day and at the end of the day closed at $165.65. Company price to sales ratio in past twelve months was calculated as 7.86 and price to cash ratio as 13.58. Allergan, Inc. (NYSE:AGN) showed a positive weekly performance of 29.62%.
Questcor Pharmaceuticals Inc (NASDAQ:QCOR) CEO Don Bailey sold 40,000 shares of Questcor Pharmaceuticals stock on the open market in a transaction that occurred on Monday, April 14th. Questcor Pharmaceuticals Inc (NASDAQ:QCOR) shares advanced 2.47% in last trading session and ended the day on $80.07. QCOR return on equity ratio is recorded as 94.20% and its return on assets is 50.60%. Questcor Pharmaceuticals Inc (NASDAQ:QCOR) yearly performance is 181.44%.
ResMed Inc (NYSE:RMD) Director Peter C. Farrell sold 75,000 shares of the stock on the open market in a transaction dated Monday, April 21st. The stock was sold at an average price of $48.01, for a total transaction of $3,600,750.00. ResMed Inc. (NYSE:RMD) shares moved down -1.79% in last trading session and was closed at $46.75 while trading in range of $46.07 – $47.52 – ResMed Inc. (NYSE:RMD) year to date (YTD) performance is -0.15%.
DexCom Inc (NASDAQ:DXCM) CFO Jess Roper sold 8,000 shares of the company’s stock in a transaction dated Monday, April 21st. The stock was sold at an average price of $36.18, for a total value of $289,440.00. Following the transaction, the chief financial officer now directly owns 87,786 shares of the company’s stock, valued at approximately $3,176,097. DexCom, Inc. (NASDAQ:DXCM) weekly performance is 5.42%. On last trading day company shares ended up $36.01. DexCom, Inc. (NASDAQ:DXCM) distance from 50-day simple moving average (SMA50) is -14.74%. Analysts mean target price for the company is $44.60.